{"nctId":"NCT00068445","briefTitle":"Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","startDateStruct":{"date":"2004-02"},"conditions":["Neurotoxicity","Pain","Unspecified Adult Solid Tumor, Protocol Specific"],"count":131,"armGroups":[{"label":"Arm I - lamotrigine","type":"EXPERIMENTAL","interventionNames":["Drug: lamotrigine"]},{"label":"Arm II - placebo","type":"OTHER","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"lamotrigine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of cancer\n* Received, or are currently receiving, neurotoxic chemotherapy, including any of the following:\n\n  * Taxanes (e.g., paclitaxel or docetaxel)\n  * Platinum-based compounds (e.g., carboplatin, cisplatin, or oxaliplatin)\n  * Vinca alkaloids (e.g., vincristine or vinblastine)\n* Experiencing pain or symptoms of peripheral neuropathy for at least 1 month attributed to chemotherapy\n\n  * Average daily pain rating of at least 4 out of 10 OR\n  * Peripheral neuropathy at least grade 1 out of 3 using ECOG sensory neuropathy rating\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nLife expectancy\n\n* At least 6 months\n\nHepatic\n\n* Bilirubin \\< 2 times upper limit of normal (ULN)\n\nRenal\n\n* Creatinine â‰¤ 1.5 times ULN\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No prior allergic reaction or intolerance to lamotrigine\n* No extreme difficulty swallowing pills\n* No other identified causes of painful paresthesia preceding chemotherapy, including any of the following:\n\n  * Radiation or malignant plexopathy\n  * Lumbar or cervical radiculopathy\n  * Pre-existing peripheral neuropathy of another etiology, such as any of the following:\n\n    * Cyanocobalamin deficiency\n    * AIDS\n    * Monoclonal gammopathy\n    * Diabetes\n    * Heavy metal poisoning amyloidosis\n    * Syphilis\n    * Hyperthyroidism or hypothyroidism\n    * Inherited neuropathy\n* No significant psychiatric illness (e.g., mania, psychosis, or schizophrenia) that would preclude study participation\n* Able to complete questionnaires\n\nPRIOR CONCURRENT THERAPY:\n\nChemotherapy\n\n* See Disease Characteristics\n* More than 7 days since prior methotrexate or other dihydrofolate inhibitors\n\nOther\n\n* More than 7 days since prior, and no concurrent use of any of the following:\n\n  * Tricyclic antidepressants (e.g., amitriptyline, nortriptyline, or desipramine)\n\n    * Concurrent selective serotonin reuptake inhibitors allowed\n  * Monoamine oxidase inhibitors\n  * Opioid analgesics\n  * Anticonvulsants (e.g., gabapentin, topiramate, valproic acid, or clonazepam)\n  * Adjuvant analgesics (e.g., mexiletine)\n\n    * Prior nonsteroidal anti-inflammatory drugs allowed\n  * Topical analgesics (e.g., lidocaine gel or patch) to the affected area\n  * Amifostine\n* More than 30 days since prior investigational agents for pain control\n* No other concurrent investigational agents for pain control","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Average Daily Pain Score as Measured Using a Pain Intensity Rating (NRS)","description":"The change in mean score for average daily pain from baseline to week 10 using the Pain Intensity Rating (NRS) are reported below. The NRS scale ranges from 0 to 10 with higher scores corresponding to having more pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.76"},{"groupId":"OG001","value":"-0.5","spread":"2.34"}]}]}]},{"type":"PRIMARY","title":"Change in Average Pain Score as Measured Using the European Cooperative Oncology Group (ECOG) Neuropathy Scale (ENS)","description":"The change in mean score for average daily pain from baseline to week 10 using the European Cooperative Oncology Group (ECOG) neuropathy scale (ENS) are reported below. The ENS scale goes from 0 to 3 with 0=none, 1=mild paresthesias, 2=mild or moderate sensory loss and/or moderate paresthesias, and 3=severe sensory loss or paresthesias that interfere with function.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.73"},{"groupId":"OG001","value":"-0.3","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"The Change in Overall Quality of Life as Measured by the Uniscale QOL From Baseline to Week 10","description":"The change in overall quality of life as measured by the Uniscale QOL (Week 10 minus Baseline) using the Wilcoxon test is reported for each arm below. The Uniscale is a score that ranges from 0 to 100, with 0 being QOL as bad as it can be and 100 being as good as it can be.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"25.15"},{"groupId":"OG001","value":"0.3","spread":"22.09"}]}]}]},{"type":"SECONDARY","title":"Change in Brief Pain Inventory (BPI) Worst Pain Score [Week 10 Minus Baseline]","description":"The average change in Brief Pain Inventory (BPI) Worst Pain scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"3.17"},{"groupId":"OG001","value":"-0.6","spread":"2.31"}]}]}]},{"type":"SECONDARY","title":"Change in Brief Pain Inventory (BPI) Least Pain Score [Week 10 Minus Baseline]","description":"The average change in Brief Pain Inventory (BPI) Least Pain scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.\n\nTime Frame:\n\nUp to 1 week post-treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.12"},{"groupId":"OG001","value":"0.1","spread":"1.97"}]}]}]},{"type":"SECONDARY","title":"Change in Brief Pain Inventory (BPI) Average Pain Score [Week 10 Minus Baseline]","description":"The average change in Brief Pain Inventory (BPI) Average Pain scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.15"},{"groupId":"OG001","value":"-0.8","spread":"2.35"}]}]}]},{"type":"SECONDARY","title":"Change in Brief Pain Inventory (BPI) Pain Now Score [Week 10 Minus Baseline]","description":"The average change in Brief Pain Inventory (BPI) Pain Now scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.77"},{"groupId":"OG001","value":"-0.3","spread":"2.22"}]}]}]},{"type":"SECONDARY","title":"Change in Brief Pain Inventory (BPI) Pain Relief Score [Week 10 Minus Baseline]","description":"The average change in Brief Pain Inventory (BPI) Pain Relief scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"28.34"},{"groupId":"OG001","value":"0.4","spread":"30.34"}]}]}]},{"type":"SECONDARY","title":"Change in Brief Pain Inventory (BPI) Pain Interference Score [Week 10 Minus Baseline]","description":"The average change in Brief Pain Inventory (BPI) Pain Interference scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.17"},{"groupId":"OG001","value":"-0.8","spread":"2.19"}]}]}]},{"type":"SECONDARY","title":"Change in POMS Total Score [Week 10 Minus Baseline]","description":"The average change in POMS Total scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The POMS scales are calculated from patient responses on 30 questions asking how they have been feeling during the past week. The scores are all transformed so that 0 is the worst possible value and 100 is the best possible value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"10.67"},{"groupId":"OG001","value":"1.3","spread":"9.09"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":61},"commonTop":["Ataxia","Dizziness","Rash desquamating","Fatigue","Depressed level of consciousness"]}}}